This week, BIOEMTECH team joins one of the most inspiring meetings dedicated to targeted radiopharmaceuticals, where experts from across Europe and beyond discuss progress from bench to bedside.
Today, we are presenting our latest work on hashtag#Actinium-225 and its daughters, a topic that has captured much of our focus lately.
Our talk, titled “Do you know where your daughters are? I know where are mine.” will explore:
- Challenges in imaging alpha emitters, particularly Ac-225, at both preclinical and clinical levels.
- Importance of monitoring the biodistribution of Ac-225 daughters for accurate dose calculations.
- In vivo imaging and ex vivo biodistribution data, showing the feasibility of following Ac-225 daughters over time.
Understanding where Actinium’s daughters go is not just a technical curiosity, it’s a step toward safer and more effective alpha therapies.
Such meetings remind us how collaborative and fast-moving this field is. And why we are excited to be part of it.